Viridian Therapeutics amends lease for new headquarters suite, extends term 5 years

Viridian Therapeutics, Inc.\DE

Fourth Amendment to Lease for 10,427 rentable sq ft at 221 Crescent St, Waltham, MA.
Base rent starts at $38,232/month in first year, escalating ~2% annually over extended term.
Tenant improvement allowance of up to $104,270; three-year extension option and right of first refusal granted.
Replaces prior lease of 10,956 sq ft in a different suite at the same address.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Viridian Therapeutics, Inc.\DE amended Fourth Amendment to Lease Agreement with Watch City Ventures MT, LLC valued at base rent $38,232.33 per month for first year, increasing 2% annually; tenant improvement allowance (effective 2024-04-08).

Action: amendment
Agreement: lease
Counterparty: Watch City Ventures MT, LLC
Value: base rent $38,232.33 per month for first year, increasing 2% annually; tenant improvement allowance
Effective: 2024-04-08

Exact text from the filing

On April 10, 2024, Viridian Therapeutics, Inc. (the “Company”) entered into a Fourth Amendment to Lease Agreement (the “Amendment”), effective April 8, 2024, with Watch City Ventures MT, LLC (“Landlord"), to amend that certain Lease, dated January 13, 2020, by and between the Company and Landlord (the “Lease"), as amended on July 6, 2021, April 13, 2022 and July 29, 2022, for the lease of an aggregate of 10,956 square feet of rentable area of the building located at 221 Crescent Street, Waltham, Massachusetts (the “Original Premises"), which serves as the Company’s headquarters.

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-24-097728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.